Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity

Abstract

Purpose To compare the effectiveness of intravitreal conbercept and ranibizumab treatment for retinopathy of prematurity (ROP). Methods In this retrospective study, the date of patients with ROP treated with intravitreal conbercept or ranibizumab from July 2012 to March 2018 with at least 12 months of follow‐up at the Eye Center in People’s Hospital of Peking University were analysed. Regression, progression or recurrence and peripheral retina vascularization were evaluated. Results In total, 283 eyes (145 infants) with conbercept treatment and 916 eyes (480 infants) with ranibizumab treatment were enrolled. In zone I ROP and aggressive posterior ROP (APROP), the recurrence prevalence was 49.09% (108/220 eyes) and 28.57% (10/33 eyes), and the recurrence interval was 7.87 ± 0.65 (5.5–9.5) weeks and 10.6 ± 1.53 (10.5–13) weeks in the ranibizumab and conbercept groups, respectively. In zone II ROP disease, the recurrence prevalence was 23.56% (164/696 eyes) and 13.31% (33/248 eyes), and the interval of recurrence was 8.40 ± 0.88 (6–10.5) weeks and 11.4 ± 1.35 (11–13.5) weeks in the ranibizumab and conbercept groups, respectively. The recurrence prevalence was significantly higher with ranibizumab in Zone I ROP and APROP (p = 0.006) and Zone II ROP (p < 0.001), and the recurrence interval was significantly longer in the conbercept group than that in the ranibizumab (p < 0.001). There was no significant difference in the rate of retinal vascularization (p = 0.441). Conclusion Conbercept and ranibizumab are effective for treating ROP. Compared with ranibizumab, conbercept resulted in less recurrence and longer treatment intervals.

Low-dose ranibizumab administration in retinopathy of prematurity

“…Thirty two of the patients were female. The mean gestational age of the patients included in the study was 26.6 (23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33) weeks, and the mean birth weight was 905 (450-1970) grams. The mean postnatal week of the rst intravitreal injection for treatment was 9.1 (4-19) weeks, and the mean follow-up time was 63 (24-250) weeks.…”

“…A second injection was applied to 46 eyes of 23 babies 4 weeks after the rst injection. Of these, 38 eyes of 19 infants recovered with re-injection, peripheral retinal vascularization was completed at an average of postnatal week 25.6 ± 4.75 (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36). eight eyes of 4 babies who were re-injected; rescue argon laser photocoagulation therapy was applied approximately 9.2 (7-11) weeks after the start of treatment.…”

Low-Dose Ranıbızumab Admınıstratıon in Retınopathy of Prematurıty

“…Thirty two of the patients were female. The mean gestational age of the patients included in the study was 26.6 (23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33) weeks, and the mean birth weight was 905 (450-1970) grams. The mean postnatal week of the rst intravitreal injection for treatment was 9.1 (4-19) weeks, and the mean follow-up time was 63 (24-250) weeks.…”

“…A second injection was applied to 46 eyes of 23 babies 4 weeks after the rst injection. Of these, 38 eyes of 19 infants recovered with re-injection, peripheral retinal vascularization was completed at an average of postnatal week 25.6 ± 4.75 (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36). eight eyes of 4 babies who were re-injected; rescue argon laser photocoagulation therapy was applied approximately 9.2 (7-11) weeks after the start of treatment.…”

The Effectiveness of Conbercept Combined with Panretinal Photocoagulation vs. Panretinal Photocoagulation in the Treatment of Diabetic Retinopathy: A Meta-Analysis

“…Although laser technology can rapidly treat the lesion area, the anti-VEGF drugs can reduce the proliferation and leakage of tissue and blood vessels caused by laser surgery. It makes up for the shortcomings of laser surgery caused by temporary increase of the apparent membrane thickness and the decrease of visual acuity [ 6 ]. As an anti-VEGF fusion protein, conbercept can not only block the angiogenesis of pathological changes but also improve the blocking of ischemia and hypoxia, blood perfusion, and inflammatory cell expression [ 7 , 8 ].…”